Association between bone scintigraphy and serum levels of tumor markers in the detection of bone disease in breast cancer patients

Journal of B.U.ON.

Volumn 12, Issue 4, 2007, Pages 505-511

  Zissimopoulos, Athanasios ^a   Matthaios, D ^a   Matthaiou, E ^b   Mantadakis, E ^c   Karaitianos, I ^d  

^a UNIVERSITY GENERAL HOSPITAL OF ALEXANDROUPOLIS   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^d SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

Bone scintigraphy; Breast cancer; CA 15 3; CEA; TPA; Tumor markers

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MEDRONATE TECHNETIUM TC 99M; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE LESION; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE SEVERITY; FALSE NEGATIVE RESULT; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; RETROSPECTIVE STUDY; SCINTILLATION CAMERA; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 38349144030     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130.
2. Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2002: Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5, version 2.0, IARC Press, Lyon, 2004.
3. Berry DA, Cronin KA, Plevritis SK et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353: 1784-1792.
4. Emens LA, Davidson NE. The follow-up of breast cancer. Semin Oncol 2003; 30: 338-348.
5. Jatoi I, Tsimelzon A, Weiss H, Clark GM, Hilsenbeck SG. Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat 2005; 89: 173-178.
6. Kattlove H, Winn RJ. Ongoing care of patients after primary treatment for their cancer. CA Cancer J Clin 2003; 53: 172-196.
7. Burstein HJ, Winer EP. Primary care for survivors of breast cancer. N Engl J Med 2000; 343: 1086-1094.
8. Galasko CSB (Ed). Skeletal Metastases. London: Butterworth, 1986.
9. Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 2005; 10: 169-180.
10. Cook JR, Fogelman I. Diagnostic nuclear medicine. In: Rubens RD, Mundy GR (Eds): Cancer and the skeleton. London: Martin Dunitz, 2000, pp 91-111.
11. Lipton A, Costa L, Ali SM, Demers LM. Bone markers in the management of metastatic bone disease. Cancer Treat Rev 2001; 27: 181-185.
12. Coleman RE. Monitoring of bone metastases. Eur J Cancer 1998; 34: 252-259.
13. Cook GJ, Fogehnan I. Skeletal metastasis from breast cancer: imaging with nuclear medicine. Semin Nucl Med 1999; 29: 69-79.
14. Crippa F, Bombardieri E, Seregni E et al. Single determination of CA 15-3 and bone scintigraphy in the diagnosis of skeletal metastasis of breast cancer. J Nucl Biol Med 1992; 36: 52-55.
15. Anonymous. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996; 14: 2843-2877.
16. Duffy MJ. CA 15-3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem 1999; 36: 579-586.
17. Cheung KL, Graves CR, Robertson JF. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 2000; 26: 91-102.
18. Nicolini A, Carpi A. Postoperative follow-up of breast cancer patients: overview of progress in the use of tumor markers. Tumor Biol 2000; 21: 235-248.
19. Soletormos G, Schioler V, Nielsen D, Skovsgaard T, Dombernowsky P. Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation. Clin Chem 1993; 39: 2077-2083.
20. Kiang DT, Greenberg LJ, Kennedy BJ. Tumor marker kinetics in the monitoring of breast cancer. Cancer 1990; 65: 193-199.
21. Hayes DF, Kiang DT, Korzun AH, Tondini C, Wood WC, Kufe DW. CA15-3 and CEA spikes during chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 1988; 7: 38 (abstr).
22. Yasasever V, Dincer M, Camlica H, Karaloglu D, Dalay N. Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastasis: special emphasis on "spiking" phenomena. Clin Biochem 1997; 30: 53-56.
23. Pentheroudakis G, Malamou-Mitsi V, Briasoulis E et al. The neutrophil, not the tumor, serum CA 15-3 elevation as a result of granulocyte-colony-stimulating factor-induced neutrophil MUC1 overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy Cancer 2004; 101: 1767-1775.
24. Hashimoto T, Matsubara F. Changes in the tumor marker concentration in female patients with hyper-, eu-, and hypothyroidism. Endocrinol Jpn 1989; 36: 873-879.
25. Symeonidis A, Kouraklis-Symeonidis A, Apostolopoulos D et al. Increased serum CA 15-3 levels in patients with megaloblastic anemia due to vitamin B12 deficiency. Oncology 2004; 67: 359-367.
26. Colomer CR, Ruibal A, Genolla J et al. Circulating CA 15-3 levels in the postsurgical follow-up breast cancer patients and in non-malignant disease. Breast Cancer Res Treat 1989; 13: 123-133.
27. Zanco P, Rota G, Sportiello V, Borsato N, Ferlin G. Diagnosis of bone and liver metastasis in breast cancer comparing tumor markers and imaging techniques. Int J Biol Markers 1989; 4: 103-105.
28. Safi F, Kohler I, Rottinger E, Beger H. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen. Cancer 1991; 68: 574-582.
29. Wojtacki J, Kruszewski WJ, Sliwinska M et al. Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases. Przeql Lek 2001; 58: 498-503.
30. Nicolini A, Ferrari P, Sagripanti A, Carpi A. The role of tumour markers in predicting skeletal metastasis in breast cancer patients with equivocal bone scintigraphy. Br J Cancer 1999; 79: 1443-1447.
31. Kokko R, Holli K, Hakama M. CA 15-3 in the follow-up of localised breast cancer: a prospective study. Eur J Cancer 2002; 38: 1189-1193.
32. Younsi N, Montravers F, Philippe C et al. CA 15-3 and bone scintigraphy in the follow-up of breast cancer. Int J Biol Markers 1997; 12: 154-157.
33. Buffaz PD, Gauchez AS, Caravel JP et al. Can tumor marker assays be a guide in the prescription of bone scan for breast and lung cancers? Eur J Nucl Med 1999; 26: 8-11.
34. Yildiz M, Oral B, Bozkurt M, Cobaner A. Relationship between bone scintigraphy and tumor markers in patients with breast cancer. Ann Nucl Med 2004; 18: 501-505.
35. Gedik GK, Kiratli PO, Tascioglu B, Aras T. Comparison of bone scintigraphy with serum tumor markers of CA 15-3 and carcinoembryonic antigen in patients with breast carcinoma. Saudi Med J 2006; 27: 317-322.